Bumetanide Treatment in 15 Children With Autism: A Randomised Waitlist-Control Study

Area of Science:

• Neuroscience
• Pharmacology
• Developmental Pediatrics

Background:

• Bumetanide, a diuretic, modulates neuronal chloride homeostasis.
• This mechanism may restore GABAergic inhibition and balance neuronal signaling.
• Preclinical and prior clinical research suggests potential benefits for autism spectrum disorder (ASD).

Purpose of the Study:

• To evaluate the efficacy of bumetanide in children with autism.
• To build upon existing preclinical and clinical findings regarding bumetanide for ASD.
• To assess the impact of bumetanide on autism-related symptoms and behaviors.

Main Methods:

• A 9-month randomized waitlist-control study involving 15 children (aged 4-12) diagnosed with autism.
• Participants were randomized to immediate bumetanide treatment or a 3-month delayed start.
• Parent-completed rating scales assessed symptoms, behaviors, and functioning at multiple time points.

Main Results:

• Two children were excluded early due to behavioral issues.
• Four of the 13 participants who started bumetanide discontinued treatment between 4-6 months.
• Four of the 9 children who completed the 9-month study showed significant clinical improvements, opting for continued treatment.

Conclusions:

• This small study suggests bumetanide may offer benefits for a subset of children with autism.
• Further research is warranted to confirm these findings in larger cohorts.
• Bumetanide's potential role in managing autism symptoms warrants continued investigation.